Halia Therapeutics to Attend the 43rd J.P. Morgan Healthcare Conference and Present at BioPharma Obesity Innovation Forum in San Francisco
LEHI, Utah, Jan. 8, 2025 /PRNewswire/ -- Halia Therapeutics, a biopharmaceutical company at the forefront of developing treatments for chronic inflammation and related disorders, announced today that its leadership team will attend and participate in a panel...
M42’s IROS and Halia Therapeutics launch clinical study on obesity treatment in the UAE
Trial underscores IROS's commitment to developing innovative therapies for unmet medical needs January 7, 2025 The study’s success could transform obesity treatment globally Positions the UAE as a hub for cutting-edge clinical research Abu Dhabi, UAE: To combat a...
Halia Therapeutics Strengthens Leadership and Clinical Operations Team
LEHI, Utah, Jan. 6, 2025 /PRNewswire/ -- Halia Therapeutics, a biopharmaceutical company at the forefront of developing treatments for chronic inflammation and related disorders, is pleased to announce key leadership additions and promotion to further its mission....
Halia Therapeutics Announces Positive Topline Data and Advances to Second Stage of Phase 2 Clinical Trial for HT-6184 in Patients with Low-Risk Myelodysplastic Syndromes (LR-MDS)
Treatment with HT-6184 has shown to improve hematological response in patients enrolled to date with LR-MDS, surpassing the threshold Halia advances to second stage expansion of Phase 2 trial LEHI, Utah, Dec. 10, 2024 /PRNewswire/ -- Halia Therapeutics, a...
Halia CEO David Bearss, Ph.D., to Present and Participate in Panel Discussion at Obesity Innovation Therapeutics Summit 2024
LEHI, Utah, Dec. 5, 2024 /PRNewswire/ -- Halia Therapeutics, Inc. (Halia), a clinical-stage biopharmaceutical company at the forefront of developing innovative treatments for chronic inflammatory diseases, today announced that David J. Bearss, Ph.D., Co-Founder,...
Halia Therapeutics to Present Promising Data at Obesity Week 2024
HT-6184 Shows Enhanced and Sustained Weight Loss with GLP-1 Agonist Combination for Obesity LEHI, Utah, October 31, 2024 /PRNewswire/—Halia Therapeutics, Inc. (Halia), a clinical-stage biopharmaceutical company pioneering innovative treatments for chronic...
Halia Therapeutics to Attend Global Health Exhibition 2024
Halia Therapeutics will showcase its LRRK2 and NEK7 inhibitors targeting Alzheimer's disease and obesity. LEHI, Utah, Oct. 21, 2024 /PRNewswire/ -- Halia Therapeutics, Inc. (Halia), a clinical-stage biopharmaceutical company pioneering innovative treatments...
Halia Therapeutics to Participate in Panel at BIO Investor Forum 2024
Dr. David J. Bearss, CEO, will partake in a panel focused on Neurodegenerative Disease Targets and Pipelines on Tuesday, October 15 at 11:00-11:50 am PT LEHI, Utah, Oct. 14, 2024 /PRNewswire/ -- Halia Therapeutics, Inc. (Halia), a clinical-stage...
PharmaVoice Recognizes Halia Therapeutics CEO David Bearss as One of the 100 Standout Leaders in the Life Sciences Industry
LEHI, Utah, Oct. 8, 2024 /PRNewswire/ -- Dr. David Bearss, CEO and Co-founder of Halia Therapeutics has been named an honoree of the 2024 PharmaVoice 100 list in the Standout Leaders category. This prestigious recognition...
Halia Therapeutics Announces First Healthy Volunteer Dosed with HT-4253, a Novel Oral LRRK2 Inhibitor Targeting Neuroinflammation in Alzheimer’s Disease
LEHI, Utah, Oct. 7, 2024 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company at the forefront of developing innovative treatments for inflammatory and neurodegenerative diseases, today announced that the first healthy...
Halia Therapeutics Reveals Promising Preclinical Obesity Data: HT-6184 and Semaglutide Combination Enhances Weight Loss and Preserves Lean Muscle Mass
LEHI, Utah, Sept. 23, 2024 -- Halia Therapeutics, Inc. (Halia), a clinical-stage biopharmaceutical company advancing novel therapies for inflammation-related diseases, today announced promising preclinical results from their investigational compound HT-6184, combined...
Halia Therapeutics to Present an Update on Phase II Clinical Trial Data of HT-6184 at the 6th Inflammasome Therapeutics Summit
Dr. David J. Bearss, CEO, will present data from the Phase II study evaluating the efficacy of HT-6184 on post-procedural inflammatory and pain responses on Thursday, September 12, 2024 LEHI, Utah, Sept. 10, 2024 /PRNewswire/ -- Halia Therapeutics, Inc....
Halia Therapeutics Joins Forces with Southern Star Research Pty Ltd to Advance Clinical Development of Novel LRRK2 Inhibitor, HT-4253 for Neurodegenerative Diseases
LEHI, Utah , Sept. 3, 2024 /PRNewswire/ -- Halia Therapeutics, Inc. (Halia), a clinical-stage biopharmaceutical company at the forefront of developing innovative treatments for inflammatory and neurodegenerative diseases, today announced a pivotal...
Halia Therapeutics’ CEO, Dr. David J. Bearss, to Present Groundbreaking Research on Chronic Inflammation and Aging at the 3rd Edition Global Longevity Federation
Lehi, UT, August 6th, 2024/PRNewswire/ – Halia Therapeutics, a clinical-stage biopharmaceutical company, today announced that Dr. David J. Bearss, President and CEO, and a renowned drug developer, will be giving an oral presentation highlighting the company’s latest...
Halia Therapeutics and Biolexis Therapeutics’ Partnership Successfully Identifies Novel Clinical Candidate Targeting NLRP3-Driven Neuroinflammation
LEHI, Utah, July 31, 2024 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, and Biolexis Therapeutics, a biotechnology company specializing...
David J. Bearss, PhD Celebrated for Dedication to the Pharmaceutical Industry
David J. Bearss, PhD channels years of expertise to his work with Halia and Biolexis Therapeutics ALPINE, UT, July 19, 2024 /24-7PressRelease/ -- David J. Bearss, PhD has been included in Marquis Who's Who. As in all Marquis Who's Who biographical volumes,...
Venture Capital Podcast Reveals Its Founder 100 for Utah
NEWS PROVIDED BY Venture Capital PodcastJun 13, 2024, 00:35 ET -- The 2024 list celebrates the top 100 founders driving innovation and growth in the Utah community -- LEHI, Utah, June 13, 2024 /PRNewswire/ -- Today, the Venture Capital Podcast...
Halia Therapeutics to Participate at BIO International Convention and The European Hematology Association Hybrid Congress
Preliminary safety, efficacy, and biomarker data from the ongoing Phase II trial evaluating HT-6184 inMDS patients will be presented at the EHA 2024 Hybrid Congress. LEHI, Utah, May 29, 2024 /PRNewswire/...
Halia Therapeutics to Unveil New Clinical Program Targeting the LRRK2 Protein for Alzheimer’s Disease at Discovery Europe 2024
CEO Dave Bearss, Ph.D., will be participating in a panel discussing the “Landscape of Drug Discovery and Impact of AI Discussion” on Wednesday, May 22, from 1:50 to 2:30 p.m. CEST Company presentation to unveil new data from HT-4253 in its new clinical Alzheimer's...
Halia Therapeutics to Present at Asia BIO 2024
*Presentation to be held on Wednesday, April 24, from 2:00 – 2:15 p.m. SGT LEHI, Utah, April 17, 2024 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat...